The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management.

ABSTRACT:

SUBMITTER: Denault MH 

PROVIDER: S-EPMC10080321 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature